Brief: Cytrx presents aldoxorubicin phase 3 clinical trial data

LadRx

04/04/2016 14:00

April 4 (Reuters) - Cytrx Corp  CYTR.O  
    * Cytrx global pivotal phase 3 clinical trial with 
aldoxorubicin achieves 191 target events triggering statistical 
data analysis 
    * Cytrx global pivotal phase 3 clinical trial with 
aldoxorubicin achieves 191 target events triggering statistical 
data analysis 
    * Plans to discuss with fda initiating a rolling new drug 
application by end of 2016 
    * Pursuant to fda approval, expects to launch aldoxorubicin 
in u.s.  In second half of 2017 
 
Source text for Eikon:  ID:nPn5MLJh5a  
Further company coverage:  CYTR.O  
 
 ((Bengaluru Newsroom; +1 646 223 8780;))